Assessing the Likelihood of Colorectal Cancer When Hemoglobin Remains Stable on Oral Iron

Pathophysiology of Cancer‑Related Iron Deficiency

Colon cancer induces both absolute and functional iron deficiency through chronic blood loss and inflammatory cytokine‑mediated hepcidin up‑regulation, which impairs iron absorption and utilization. 1
In cancer patients, oral iron is poorly effective because hepcidin blocks intestinal iron absorption and sequesters iron in macrophages. 1
Cancer‑related inflammation prevents an adequate response to oral iron by internalising ferroportin, thereby blocking iron export from enterocytes. 1

Oral iron should be considered only when a patient has absolute iron deficiency (ferritin < 100 ng/mL) and a non‑inflammatory state (CRP < 5 mg/L). 1
Patients with colorectal cancer typically exhibit elevated inflammatory markers, rendering oral iron largely ineffective. 1

The WHO defines anemia as hemoglobin < 13 g/dL in men and < 12 g/dL in non‑pregnant women; a value of 13 g/dL is therefore at or above the anemia threshold. 2
A rapid rise in hemoglobin (≥10 g/L within 2 weeks) after oral iron strongly suggests absolute iron deficiency without significant inflammation. 2
Sustained hemoglobin stability for 13 months indicates a balance between iron intake and any losses, a pattern unlikely in the presence of progressive malignancy. 2

Even mild anemia or non‑anemic iron deficiency can be a marker for colorectal cancer, though the risk is lower than with severe anemia. 3
Age, sex, hemoglobin concentration, and mean corpuscular volume are independent predictors of gastrointestinal cancer risk and should be evaluated together. 3
The threshold for endoscopic investigation should be low in men, post‑menopausal women, and individuals with gastrointestinal symptoms or a family history of GI malignancy, even when anemia is absent. 3

Menstrual blood loss in pre‑menopausal women may explain stable hemoglobin despite supplementation. 3
Dietary iron insufficiency can contribute to persistent iron deficiency despite oral therapy. 1
Malabsorption syndromes (e.g., celiac disease) account for 3–5 % of iron‑deficiency anemia cases. 3
Other non‑malignant gastrointestinal sources of blood loss such as peptic ulcer disease or angiodysplasia should be considered. 3

Male gender or post‑menopausal status. 3
Presence of any gastrointestinal symptoms. 3
Family history of gastrointestinal malignancy. 3
Ferritin < 45 µg/L in the setting of chronic inflammation (specificity = 0.92 for iron deficiency). 3
Microcytosis with normal iron studies (warranting hemoglobinopathy screening). 3

Age‑appropriate colorectal cancer screening remains indicated when additional risk factors are present, even if hemoglobin has been stable on oral iron for an extended period. 3